{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-22-015284","form_type":"8-K","ticker":"NDRA","cik":"0001681682","company_name":"ENDRA Life Sciences Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.696777+00:00","generated_at":"2026-06-21T20:36:36.685223+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"ENDRA Q3 net loss $3.4M; cash $8.0M; 95 TAEUS scans YTD, De Novo submission near","bullets":["Net loss $3.4 million ($0.05 per share) vs $2.7 million loss ($0.06) in Q3 2021.","Cash and equivalents $8.0 million as of Sept 30, 2022; operating expenses rose to $3.4M from $2.7M.","Nearly doubled TAEUS scans to 95 YTD; collecting final data for FDA De Novo submission for liver device.","Expanded IP portfolio to 56 issued patents; eight new patents added in Q3.","Management reiterates cash sufficient to fund through key milestones including European commercialization and U.S. regulatory submission."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-22-015284","json":"https://secwatch.observer/filing/0001654954-22-015284.json","markdown":"https://secwatch.observer/filing/0001654954-22-015284.md","text":"https://secwatch.observer/filing/0001654954-22-015284.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681682/000165495422015284/0001654954-22-015284-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681682/000165495422015284/endra_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T20:36:36.685223+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"67fa4a8e5a6d301a8fb9cec3c81b1f93ffe1f0e0","claim":"ENDRA Life Sciences Inc. reported third quarter of 2022 results: net income $3.4 million, EPS $0.05 per share.","evidence_excerpt":"Net loss in the third quarter of 2022 was $3.4 million, or $0.05 per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1681682/000165495422015284/0001654954-22-015284-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter of 2022"},{"label":"Net income","value":"$3.4 million"},{"label":"EPS","value":"$0.05 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}